• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

MMWR Update: The Impact of Vaccination on HPV Prevalence Among Young Women in the US

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Data through 2016 demonstrates decreased HPV prevalence following introduction of the HPV vaccine
    • 2006: Introduction of the quadrivalent vaccine (4vHPV)
    • 2015: Five additional types of HPV were targeted with the nine valent vaccine (9vHPV)
  • Rosenblum et al. (MMWR, 2021) provide the latest update on HPV prevalence among females through 2018

METHODS:

  • Cross-sectional survey
    • National Health and Nutrition Examination Survey (NHANES)
  • Population
    • Females aged 14 to 38 years
  • Exposure
    • Self- or parent-reported vaccination history
  • Study design
    • Data on HPV prevalence were analyzed in 4-year periods
      • Pre-vaccine: 2003-2006
      • Post-vaccine: 2007 to 2010 | 2011 to 2014 | 2015 to 2018
    • Age groups: 14 to 19 | 20 to 24 | 25 to 29 | 30 to 34 years
    • Prevalence ratios (PRs) and adjusted prevalence ratios (aPRs) were calculated to compare time periods
  • Primary outcome
    • HPV prevalence, based on type
      • 4vHPV types
      • Five additional 9vHPV types
      • Non-4vHPV types
      • Non-9vHPV types

RESULTS:

Age 14 to 19 Years

  • From 2003 to 2006 to 2015 to 2018, prevalence of 4vHPV-type infection decreased 88%
    • 2003 to 2006: 11.5%
    • 2015 to 2018: 1.1%
    • aPR 0.12 (95% CI, 0.06 to 0.26)
  • The prevalence of five additional 9vHPV types in this age group decreased 65%
    • 2003 to 2006: 8.4%
    • 2015 to 2018: 2.3%
    • aPR 0.35 (95% CI, 0.18 to 0.65)

Age 20 to 24 years

  • 4vHPV types decreased 81%
    • 2003 to 2006: 8.5%
    • 2015 to 2018: 3.3%
    • aPR 0.19 (95% CI, 0.09 to 0.40)
  • However, prevalence of the 5 additional 9vHPV types did not significantly decline in this age group

Age >24 years

  • Among females in older age groups, there was no statistically significant differences in the prevalence of 4vHPV or the five additional 9vHPV types between 2003 to 2006 to 2015 to 2018

Analysis Based on Vaccination

  • 4vHPV-type prevalence decreased in both vaccinated and unvaccinated individuals (sexually experienced)
    • ≥1 HPV vaccine dose
      • 14 to 19 years: 97% prevalence decrease
      • 20 to 24 years: 86% prevalence decrease
    • No vaccination
      • 14 to 19 years: 87% prevalence decrease
      • 20 to 24 years:  65% prevalence decrease

CONCLUSION:

  • In this 2018 update, HPV vaccine continues to impact the prevalence of 4vHPV types in the US
  • Incidence of 4vHPV types has declined in unvaccinated individuals aged 14 to 19 and 20 to 24
  • The authors conclude

Significant declines among unvaccinated females suggest herd effects

HPV vaccination is a critical prevention tool against HPV infection, anogenital warts, and HPV-attributable precancers and cancers

HPV vaccination is highly effective and is recommended routinely at age 11 to 12 years and through 26 years for persons not already vaccinated

Learn More – Primary Sources:

Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

HPV Vaccines: Cochrane Reviews Looks at the Evidence with Multi-Year Follow-Up
HPV Vaccine and Maternal and Infant Outcomes
The HPV Vaccine Leads to a Reduction in Cervical Precancers in Young Women in the U.S.

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site